These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573 [TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600 [TBL] [Abstract][Full Text] [Related]
13. Perspective on the current use of bortezomib in multiple myeloma. San-Miguel J; Bladé J Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272 [No Abstract] [Full Text] [Related]
14. The role of bortezomib in the treatment of lymphoma. Barr P; Fisher R; Friedberg J Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474 [TBL] [Abstract][Full Text] [Related]
15. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Riccioni R; Senese M; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Lo-Coco F; Foà R; Peschle C; Testa U Br J Haematol; 2007 Oct; 139(2):194-205. PubMed ID: 17897295 [TBL] [Abstract][Full Text] [Related]
16. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071 [TBL] [Abstract][Full Text] [Related]
17. [Use of proteasome inhibitors in the treatment of patients with multiple myeloma]. Rukavitsyn OA Ter Arkh; 2006; 78(10):40-4. PubMed ID: 17180936 [No Abstract] [Full Text] [Related]
18. Bortezomib in multiple myeloma. Meisler AI N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013 [No Abstract] [Full Text] [Related]
19. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253 [TBL] [Abstract][Full Text] [Related]